Cogent Biosciences, INC 8-K filings

Cogent Biosciences has filed a prospectus supplement to offer up to $400 million in common stock through an at-the-market (ATM) offering.

Cogent Biosciences announced strong Q2 2026 financial results, highlighting progress in bezuclastinib development for GIST and Systemic Mastocytosis, with key PDUFA dates approaching and a cash runway extending into late 2028.

Cogent Biosciences announced Q1 2026 financial results, highlighting progress in bezuclastinib development for Systemic Mastocytosis and GIST, with a strong cash position extending into 2028.

Cogent Biosciences announced strong 2025 financial results and significant progress in its bezuclastinib regulatory submissions for multiple indications, including NonAdvSM, GIST, and AdvSM.

Cogent Biosciences announced positive full results from its SUMMIT trial in nonadvanced systemic mastocytosis and top-line results from its APEX trial in advanced systemic mastocytosis for bezuclastinib.

Cogent Biosciences, Inc. completed a public offering of $230 million in 1.625% Convertible Senior Notes due 2031, enhancing its financial flexibility.

Cogent Biosciences successfully priced concurrent public offerings of common stock and convertible senior notes, raising approximately $546.8 million in net proceeds to fund its pipeline and operations.

Cogent Biosciences announced highly positive Phase 3 PEAK trial results for bezuclastinib in imatinib-resistant GIST, showing significant progression-free survival and objective response rate benefits.

Cogent Biosciences reports strong Q3 2025 financial results and significant progress in its clinical pipeline, with key data readouts and an NDA filing expected by year-end.

Cogent Biosciences, Inc. has entered into a new lease agreement for approximately 31,518 square feet of office space in Waltham, Massachusetts, to serve as its new corporate headquarters.

Cogent Biosciences announced positive top-line results from its SUMMIT trial for bezuclastinib in NonAdvanced Systemic Mastocytosis, alongside a strengthened cash position to fund operations into 2027.

Cogent Biosciences announced highly positive top-line results from its SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis, alongside a successful $230 million public offering, significantly bolstering its financial position and paving the way for an FDA NDA submission.

Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib for non-advanced systemic mastocytosis, demonstrating clinically meaningful and highly statistically significant improvements across primary and key secondary endpoints.

Cogent Biosciences, Inc. has secured a non-dilutive term loan facility of up to $400 million, with an initial $50 million funded, to support its growth strategy, including the anticipated 2026 launch of bezuclastinib and upcoming pivotal trial results.

Cogent Biosciences, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where key proposals including officer exculpation and director elections were approved, and provided an update on its clinical pipeline and financial outlook.

Cogent Biosciences announces its Q1 2025 financial results, highlighting key clinical trial milestones and a strong cash position to fund operations into late 2026.

Cogent Biosciences reports promising clinical trial results and a strong financial position, anticipating key data readouts and a potential NDA submission by the end of 2025.

Cogent Biosciences reported positive updated data from Phase 2 trials of bezuclastinib for advanced and non-advanced systemic mastocytosis at the ASH 2024 conference.

Cogent Biosciences announced the completion of enrollment in a Phase 3 trial, initiation of a Phase 1 trial, and a strong cash position to fund operations into late 2026.

Cogent Biosciences announced the completion of enrollment in its Phase 3 PEAK trial for gastrointestinal stromal tumors and accelerated enrollment for its Phase 2 SUMMIT trial in nonadvanced systemic mastocytosis.

Cogent Biosciences announced positive clinical trial updates and its second quarter 2024 financial results, highlighting progress in its key programs and a strong cash position.

Cogent Biosciences has secured FDA agreement on its patient-reported outcome measure for a key clinical trial and remains on track for multiple trial milestones.

Cogent Biosciences' stockholders approved an increase in authorized shares and elected directors at the 2024 Annual Meeting.

Cogent Biosciences announced its first quarter 2024 financial results, highlighting a strong cash position and continued progress in its clinical trials for bezuclastinib.

Cogent Biosciences has agreed to exchange 8.3 million common shares for 8,300 shares of Series B preferred stock with existing stockholders, increasing the authorized preferred shares.

Cogent Biosciences announced positive clinical trial updates for its lead drug bezuclastinib and secured funding to extend operations into 2027.

Cogent Biosciences has successfully raised approximately $225 million through a private placement to fund its clinical programs and extend its cash runway into 2027.